Division of Nephrology, Department of Medicine and Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada.
Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Ren Fail. 2024 Dec;46(2):2419960. doi: 10.1080/0886022X.2024.2419960. Epub 2024 Oct 30.
Early diagnosis of acute kidney injury (AKI) is limited with current tools. MicroRNAs (miRNAs) are implicated in AKI pathogenesis in preclinical models, but less is known about their role in humans. We conducted a systematic review to identify dysregulated miRNAs in humans with AKI.
We searched Ovid MEDLINE, Embase, Web of Science, and CENTRAL (August 21, 2023) for studies of human subjects with AKI. We excluded reviews and pre-clinical studies without human data. The primary outcome was dysregulated miRNAs in AKI. Two reviewers screened abstracts, reviewed full texts, performed data extraction and quality assessment (Newcastle Ottawa Scale).
We screened 2,456 reports and included 92 for synthesis without meta-analysis. All studies except one were observational. Studies were grouped by etiology of AKI: cardiac surgery-associated (CS-AKI, = 13 studies), sepsis ( = 25), nephrotoxic ( = 9), kidney transplant ( = 26), and other causes ( = 19). In total, 128 miRNAs were identified to be dysregulated across AKI studies (45 miRNAs upregulated, 55 downregulated, 28 both). miR-21 was the most frequently reported ( = 17 studies) and it was increased in all etiologies except CS-AKI where it was decreased ( = 3 studies). Study limitations included bias due to targeted approaches, absence of clinical data/controls, and miRNA normalization methods. Overall study quality was fair (median 5/9, range 2-8 points).
Dysregulated miRNAs, particularly miR-21, have potential as AKI biomarkers. These results should be interpreted cautiously due to methodological limitations. Standardized methods and unbiased approaches are needed to validate candidate miRNA biomarkers. International Prospective Register of Systematic Reviews (PROSPERO CRD42020201253).
目前的工具对急性肾损伤(AKI)的早期诊断有限。微小 RNA(miRNA)在临床前模型中与 AKI 的发病机制有关,但对其在人类中的作用知之甚少。我们进行了一项系统评价,以确定 AKI 患者中失调的 miRNA。
我们在 Ovid MEDLINE、Embase、Web of Science 和 CENTRAL(2023 年 8 月 21 日)中搜索了 AKI 人类受试者的研究。我们排除了没有人类数据的综述和临床前研究。主要结局是 AKI 中失调的 miRNA。两名审查员筛选摘要、审查全文、进行数据提取和质量评估(纽卡斯尔-渥太华量表)。
我们筛选了 2456 份报告,其中 92 份进行了无荟萃分析的综合分析。除一项外,所有研究均为观察性研究。研究按 AKI 的病因分组:心脏手术相关(CS-AKI,13 项研究)、脓毒症(25 项研究)、肾毒性(9 项研究)、肾移植(26 项研究)和其他原因(19 项研究)。总共鉴定出 128 个 miRNA 在 AKI 研究中失调(45 个上调,55 个下调,28 个同时上调和下调)。miR-21 是最常报道的(17 项研究),除 CS-AKI 外,在所有病因中均增加(3 项研究),CS-AKI 中减少(3 项研究)。研究局限性包括由于靶向方法、缺乏临床数据/对照以及 miRNA 归一化方法导致的偏倚。总体研究质量为中等(中位数 5/9,范围 2-8 分)。
失调的 miRNA,特别是 miR-21,可能成为 AKI 的生物标志物。由于方法学限制,这些结果应谨慎解释。需要标准化方法和无偏方法来验证候选 miRNA 生物标志物。国际前瞻性系统评价注册处(PROSPERO CRD42020201253)。